Chemo Group subsidiary mAbxience is a biopharmaceutical firm specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.
By using Chemo Group’s infrastructure, mAbxience will be responsible for regulatory submissions, using BOW015’s existing data package, and eventual commercialization in these select Latin American markets.
Epirus Biopharmaceuticals president and chief executive officer Amit Munshi said: "We are pleased to work with a strong regional partner to register and commercialize our infliximab biosimilar.
"We are committed to improving patient access to biosimilars globally and believe mAbxience has the right focus and infrastructure in these markets to advance this important medicine."
mAbxience CEO Carlos Banado said: "We are confident in our ability to execute and advance BOW015, given the high quality of the existing data package and our expertise within these regions."